secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001104659-26-034907
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MetaVia reports FY2025 net loss $13.0M; DA-1726 Phase 1 shows 9.1% weight loss
------------------------------------------------------------------------------

- Net loss of $13.0M ($7.35/share) vs $27.6M ($39.13/share) in FY2024; revenue not reported.
- Cash and cash equivalents $10.3M at Dec 31, 2025; with Jan 2026 $9.3M offering, funds operations into Q4 2026.
- DA-1726 48 mg Phase 1 data: 9.1% weight loss, reduced waist circumference, improved glucose and liver stiffness.
- Phase 1 Part 3 titration study (48 mg and 64 mg) IRB approved; dosing starts April 2026, data expected Q4 2026.
- Vanoglipel Phase 2a MASH data presented at AASLD; end-of-Phase 2 FDA meeting being scheduled.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000110465926034907/0001104659-26-034907-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000110465926034907/mtva-20260326x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-034907

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer